Cara Therapeutics (CARA) Stock Forecast, Price Target & Predictions
CARA Stock Forecast
Cara Therapeutics stock forecast is as follows: an average price target of $14.50 (represents a 4401.71% upside from CARA’s last price of $0.32) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
CARA Price Target
The average price target for Cara Therapeutics (CARA) is $14.50 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $30.00 to $1.00. This represents a potential 4401.71% upside from CARA's last price of $0.32.
CARA Analyst Ratings
According to 4 Wall Street analysts, Cara Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for CARA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (50.00%), 1 'Hold' (25.00%), 1 'Sell' (25.00%), and 0 'Strong Sell' (0.00%).
Cara Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 13, 2024 | Sumant Kulkarni | Canaccord Genuity | $1.00 | $0.68 | 47.17% | 210.46% |
| Jun 12, 2024 | Annabel Samimy | Stifel Nicolaus | $1.00 | $0.68 | 47.17% | 210.46% |
| May 10, 2022 | Oren Livnat | H.C. Wainwright | $30.00 | $9.23 | 225.03% | 9213.88% |
| Mar 03, 2022 | Joseph Stringer | Needham | $26.00 | $11.08 | 134.66% | 7972.03% |
The latest Cara Therapeutics stock forecast, released on Jun 13, 2024 by Sumant Kulkarni from Canaccord Genuity, set a price target of $1.00, which represents a 47.17% increase from the stock price at the time of the forecast ($0.68), and a 210.46% increase from CARA last price ($0.32).
Cara Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $1.00 | $1.00 |
| Last Closing Price | $0.32 | $0.32 | $0.32 |
| Upside/Downside | -100.00% | 210.46% | 210.46% |
In the current month, the average price target of Cara Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cara Therapeutics's last price of $0.32. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 13, 2024 | Needham | Buy | Buy | Hold |
| Jun 13, 2024 | H.C. Wainwright | - | Neutral | Downgrade |
| Jun 13, 2024 | Needham | Buy | Hold | Downgrade |
| Jun 13, 2024 | Canaccord Genuity | Underperform | Negative | Downgrade |
| May 14, 2024 | Needham | Buy | Buy | Hold |
| May 14, 2024 | Canaccord Genuity | Underperform | Underperform | Hold |
| Mar 28, 2024 | Needham | Buy | Buy | Hold |
| Mar 28, 2024 | Canaccord Genuity | Underperform | Underperform | Hold |
| Mar 05, 2024 | Needham | Buy | Buy | Hold |
| Dec 19, 2023 | Piper Sandler | Buy | Buy | Hold |
Cara Therapeutics's last stock rating was published by Needham on Jun 13, 2024. The company gave CARA a "Buy" rating, the same as its previous rate.
Cara Therapeutics Financial Forecast
Cara Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $3.00M | $4.87M | $6.93M | $6.17M | $3.26M | $10.81M | - | $4.79M | $821.00K | $20.27M | - | $1.94M | $112.09M | $9.27M | $5.63M | $8.09M | $4.51M | $5.79M | $5.21M | $4.38M | $5.06M | $2.87M |
| Avg Forecast | $600.00K | $800.00K | $1.00M | $1.20M | $1.69M | $2.02M | $1.18M | $1.68M | $9.42M | $9.95M | $6.50M | $4.89M | $14.50M | $8.84M | $21.11M | $2.64M | $1.46M | $15.59M | $2.59M | $3.02M | $5.97M | $4.73M | $5.01M | $4.71M | $5.39M | $4.84M | $3.06M | $3.29M | $4.96M | $1.77M |
| High Forecast | $1.02M | $1.36M | $1.70M | $2.03M | $2.87M | $3.67M | $1.99M | $2.85M | $15.78M | $16.87M | $11.01M | $8.29M | $24.59M | $14.98M | $21.11M | $5.30M | $2.93M | $31.36M | $5.22M | $6.08M | $12.02M | $9.51M | $10.09M | $9.46M | $10.83M | $9.74M | $6.14M | $6.62M | $5.96M | $2.12M |
| Low Forecast | $310.34K | $413.79K | $517.24K | $620.69K | $874.31K | $1.12M | $608.27K | $870.93K | $4.39M | $5.15M | $3.36M | $2.53M | $7.50M | $4.57M | $21.11M | $284.66K | $157.43K | $1.68M | $279.91K | $326.56K | $645.03K | $510.47K | $541.31K | $508.01K | $581.51K | $522.90K | $329.80K | $355.57K | $3.97M | $1.41M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 16 | 11 | 8 | 8 | 12 | 7 | 12 | 7 | 7 | 17 | 13 |
| Surprise % | - | - | - | - | - | - | - | - | 0.32% | 0.49% | 1.07% | 1.26% | 0.22% | 1.22% | - | 1.82% | 0.56% | 1.30% | - | 0.64% | 18.76% | 1.96% | 1.12% | 1.72% | 0.84% | 1.19% | 1.70% | 1.33% | 1.02% | 1.63% |
Cara Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $1.68M, with a low forecast of $870.93K, and a high forecast of $2.85M. CARA's average Quarter revenue forecast represents a -43.95% decrease compared to the company's last Quarter revenue of $3.00M (Dec 23).
Cara Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 16 | 11 | 8 | 8 | 12 | 7 | 12 | 7 | 7 | 17 | 13 |
| EBITDA | - | - | - | - | - | - | - | - | $-32.61M | $-28.03M | $-31.48M | $-27.59M | $-31.31M | $-23.84M | - | $-27.85M | $-33.32M | $-951.00K | $-30.68M | $-23.24M | $78.72M | $-16.59M | $-25.20M | $-29.00M | $-28.73M | $-33.12M | $-23.14M | $-22.00M | $-19.39M | $-17.23M |
| Avg Forecast | $-475.03K | $-633.37K | $-791.72K | $-950.06K | $-1.34M | $-1.60M | $-931.06K | $-25.10M | $-7.46M | $-7.88M | $-5.14M | $-26.85M | $-11.48M | $-1.56M | $-16.71M | $-28.71M | $-1.15M | $-1.67M | $-27.45M | $-27.96M | $-4.73M | $-21.15M | $-30.09M | $-29.00M | $-30.91M | $-23.98M | $-24.28M | $-22.75M | $-19.00M | $-7.11M |
| High Forecast | $-245.70K | $-327.61K | $-409.51K | $-491.41K | $-692.21K | $-887.31K | $-481.58K | $-20.08M | $-3.47M | $-4.08M | $-2.66M | $-21.48M | $-5.94M | $-1.25M | $-16.71M | $-22.97M | $-124.64K | $-1.34M | $-21.96M | $-22.37M | $-510.68K | $-16.92M | $-24.07M | $-23.20M | $-24.72M | $-19.19M | $-19.43M | $-18.20M | $-15.20M | $-5.69M |
| Low Forecast | $-805.37K | $-1.07M | $-1.34M | $-1.61M | $-2.27M | $-2.91M | $-1.58M | $-30.12M | $-12.50M | $-13.36M | $-8.72M | $-32.21M | $-19.47M | $-1.87M | $-16.71M | $-34.45M | $-2.32M | $-2.00M | $-32.94M | $-33.56M | $-9.51M | $-25.38M | $-36.11M | $-34.80M | $-37.09M | $-28.78M | $-29.14M | $-27.30M | $-22.80M | $-8.53M |
| Surprise % | - | - | - | - | - | - | - | - | 4.37% | 3.56% | 6.12% | 1.03% | 2.73% | 15.28% | - | 0.97% | 28.86% | 0.57% | 1.12% | 0.83% | -16.64% | 0.78% | 0.84% | 1.00% | 0.93% | 1.38% | 0.95% | 0.97% | 1.02% | 2.42% |
16 analysts predict CARA's average Quarter EBITDA for Mar 21 to be $-27.96M, with a high of $-22.37M and a low of $-33.56M. This is -135.53% lower than Cara Therapeutics's previous annual EBITDA (Dec 20) of $78.72M.
Cara Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 16 | 11 | 8 | 8 | 12 | 7 | 12 | 7 | 7 | 17 | 13 |
| Net Income | - | - | - | - | - | - | - | - | $-32.34M | $-28.03M | $-31.48M | $-25.68M | $-29.37M | $-22.52M | - | $-27.59M | $-33.38M | $-1.01M | $-30.75M | $-23.30M | $78.91M | $-16.51M | $-25.07M | $-28.92M | $-28.61M | $-32.84M | $-22.96M | $-21.96M | $-19.40M | $-17.19M |
| Avg Forecast | $-10.94M | $-12.59M | $-11.49M | $-10.94M | $-10.76M | $-13.13M | $-14.99M | $-25.16M | $-24.41M | $-28.46M | $-29.46M | $-26.91M | $-18.76M | $-1.66M | $-14.27M | $-28.78M | $-27.86M | $-1.78M | $-27.39M | $-28.04M | $171.63M | $-21.05M | $-29.93M | $-28.92M | $-30.78M | $-23.78M | $-24.09M | $-22.72M | $-19.01M | $-7.09M |
| High Forecast | $-4.08M | $-4.69M | $-4.28M | $-4.08M | $-4.01M | $-12.08M | $-5.58M | $-20.13M | $-23.55M | $-10.60M | $-10.97M | $-21.53M | $-6.99M | $-1.33M | $-14.27M | $-23.02M | $4.45M | $-1.42M | $-21.91M | $-22.43M | $205.95M | $-16.84M | $-23.95M | $-23.14M | $-24.62M | $-19.03M | $-19.27M | $-18.17M | $-15.21M | $-5.67M |
| Low Forecast | $-20.84M | $-23.97M | $-21.88M | $-20.84M | $-20.49M | $-13.66M | $-28.55M | $-30.19M | $-25.69M | $-54.18M | $-56.09M | $-32.29M | $-35.72M | $-1.99M | $-14.27M | $-34.53M | $-64.49M | $-2.13M | $-32.87M | $-33.65M | $137.30M | $-25.26M | $-35.92M | $-34.71M | $-36.93M | $-28.54M | $-28.91M | $-27.26M | $-22.81M | $-8.51M |
| Surprise % | - | - | - | - | - | - | - | - | 1.32% | 0.99% | 1.07% | 0.95% | 1.57% | 13.54% | - | 0.96% | 1.20% | 0.57% | 1.12% | 0.83% | 0.46% | 0.78% | 0.84% | 1.00% | 0.93% | 1.38% | 0.95% | 0.97% | 1.02% | 2.42% |
Cara Therapeutics's average Quarter net income forecast for Mar 21 is $-28.04M, with a range of $-33.65M to $-22.43M. CARA's average Quarter net income forecast represents a -135.53% decrease compared to the company's last Quarter net income of $78.91M (Dec 20).
Cara Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 16 | 11 | 8 | 8 | 12 | 7 | 12 | 7 | 7 | 17 | 13 |
| SG&A | - | - | - | - | - | - | - | - | $6.59M | $6.75M | $7.54M | $6.86M | $6.43M | $6.91M | - | $9.31M | $11.48M | $5.85M | $5.62M | $6.37M | $6.66M | $5.22M | $5.41M | $4.56M | $4.62M | $4.23M | $4.99M | $3.91M | $3.23M | $3.69M |
| Avg Forecast | $524.62K | $699.49K | $874.36K | $1.05M | $1.48M | $1.76M | $1.03M | $1.47M | $8.24M | $8.70M | $5.68M | $4.28M | $12.68M | $7.73M | $18.45M | $2.31M | $1.28M | $10.27M | $2.27M | $2.64M | $5.22M | $4.13M | $4.38M | $4.56M | $4.97M | $3.06M | $2.67M | $2.88M | $3.16M | $1.52M |
| High Forecast | $889.43K | $1.19M | $1.48M | $1.78M | $2.51M | $3.21M | $1.74M | $2.50M | $13.80M | $14.75M | $9.63M | $7.25M | $21.50M | $13.10M | $18.45M | $4.64M | $2.56M | $12.32M | $4.56M | $5.32M | $10.51M | $8.32M | $8.82M | $5.47M | $5.96M | $3.67M | $5.37M | $5.79M | $3.79M | $1.82M |
| Low Forecast | $271.35K | $361.80K | $452.25K | $542.71K | $764.46K | $979.93K | $531.85K | $761.51K | $3.84M | $4.50M | $2.94M | $2.21M | $6.56M | $4.00M | $18.45M | $248.89K | $137.65K | $8.21M | $244.74K | $285.53K | $563.99K | $446.33K | $473.30K | $3.65M | $3.97M | $2.45M | $288.37K | $310.90K | $2.53M | $1.22M |
| Surprise % | - | - | - | - | - | - | - | - | 0.80% | 0.78% | 1.33% | 1.60% | 0.51% | 0.89% | - | 4.04% | 9.00% | 0.57% | 2.48% | 2.41% | 1.27% | 1.26% | 1.23% | 1.00% | 0.93% | 1.38% | 1.87% | 1.36% | 1.02% | 2.42% |
Cara Therapeutics's average Quarter SG&A projection for Mar 24 is $1.47M, based on 2 Wall Street analysts, with a range of $761.51K to $2.50M. The forecast indicates a -77.65% fall compared to CARA last annual SG&A of $6.59M (Dec 23).
Cara Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Sep 18 | Jun 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 16 | 11 | 8 | 8 | 12 | 7 | 12 | 7 | 7 | 17 | 13 |
| EPS | - | - | - | - | - | - | - | - | $-0.59 | $-0.00 | $-0.00 | $-0.48 | $-0.55 | $-0.42 | - | $-0.52 | $-0.63 | $-0.02 | $-0.61 | $-0.47 | $1.68 | $-0.35 | $-0.54 | $-0.62 | $-0.61 | $-0.74 | $-0.58 | $-0.56 | $-0.51 | $-0.52 |
| Avg Forecast | $-0.20 | $-0.23 | $-0.21 | $-0.20 | $-0.20 | $-0.24 | $-0.27 | $-0.40 | $-0.45 | $-0.52 | $-0.54 | $-0.51 | $-0.34 | $-0.41 | $-0.26 | $-0.55 | $-0.51 | $-0.39 | $-0.55 | $-0.57 | $0.36 | $-0.60 | $-0.67 | $-0.60 | $-0.66 | $-0.58 | $-0.61 | $-0.58 | $-0.49 | $-0.13 |
| High Forecast | $-0.07 | $-0.09 | $-0.08 | $-0.07 | $-0.07 | $-0.22 | $-0.10 | $-0.15 | $-0.43 | $-0.19 | $-0.20 | $-0.19 | $-0.13 | $-0.15 | $-0.26 | $0.09 | $0.08 | $0.06 | $0.09 | $0.09 | $0.84 | $0.10 | $0.11 | $0.10 | $0.11 | $0.09 | $0.10 | $0.09 | $-0.39 | $-0.11 |
| Low Forecast | $-0.38 | $-0.44 | $-0.40 | $-0.38 | $-0.37 | $-0.25 | $-0.52 | $-0.76 | $-0.47 | $-0.99 | $-1.02 | $-0.98 | $-0.65 | $-0.78 | $-0.26 | $-1.28 | $-1.18 | $-0.89 | $-1.27 | $-1.33 | $-0.06 | $-1.38 | $-1.54 | $-1.39 | $-1.53 | $-1.34 | $-1.42 | $-1.33 | $-0.59 | $-0.16 |
| Surprise % | - | - | - | - | - | - | - | - | 1.32% | 0.00% | 0.00% | 0.94% | 1.60% | 1.02% | - | 0.94% | 1.23% | 0.05% | 1.11% | 0.82% | 4.62% | 0.59% | 0.81% | 1.03% | 0.93% | 1.28% | 0.94% | 0.97% | 1.04% | 4.00% |
According to 16 Wall Street analysts, Cara Therapeutics's projected average Quarter EPS for Mar 21 is $-0.57, with a low estimate of $-1.33 and a high estimate of $0.09. This represents a -134.07% decrease compared to CARA previous annual EPS of $1.68 (Dec 20).
Cara Therapeutics Peer Comparison by Price Target
CARA Forecast FAQ
Is Cara Therapeutics a good buy?
Yes, according to 4 Wall Street analysts, Cara Therapeutics (CARA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 50.00% of CARA's total ratings.
What is CARA's price target?
Cara Therapeutics (CARA) average price target is $14.5 with a range of $1 to $30, implying a 4401.71% from its last price of $0.322. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Cara Therapeutics stock go up soon?
According to Wall Street analysts' prediction for CARA stock, the company can go up by 4401.71% (from the last price of $0.322 to the average price target of $14.5), up by 9213.88% based on the highest stock price target, and up by 210.46% based on the lowest stock price target.
Can Cara Therapeutics stock reach $0?
CARA's average twelve months analyst stock price target of $14.5 supports the claim that Cara Therapeutics can reach $0 in the near future.
What are Cara Therapeutics's analysts' financial forecasts?
Cara Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $6.57M (high $11.39M, low $3.47M), average EBITDA is $-28.967M (high $-22.141M, low $-36.876M), average net income is $-64.049M (high $-41.801M, low $-92.89M), average SG&A $5.74M (high $9.96M, low $3.04M), and average EPS is $-1.109 (high $-0.544, low $-1.904). CARA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.6M (high $6.1M, low $1.86M), average EBITDA is $-2.85M (high $-1.474M, low $-4.832M), average net income is $-45.969M (high $-17.119M, low $-87.525M), average SG&A $3.15M (high $5.34M, low $1.63M), and average EPS is $-0.84 (high $-0.313, low $-1.599).
Did the CARA's actual financial results beat the analysts' financial forecasts?
Based on Cara Therapeutics's last annual report (Dec 2023), the company's revenue was $20.97M, which missed the average analysts forecast of $30.76M by -31.83%. Apple's EBITDA was $-121M, beating the average prediction of $-47.325M by 156.73%. The company's net income was $-119M, beating the average estimation of $-109M by 8.50%. Apple's SG&A was $27.78M, beating the average forecast of $26.89M by 3.29%. Lastly, the company's EPS was $-2.19, beating the average prediction of $-2.018 by 8.54%. In terms of the last quarterly report (Dec 2023), Cara Therapeutics's revenue was $3M, missing the average analysts' forecast of $9.42M by -68.12%. The company's EBITDA was $-32.607M, beating the average prediction of $-7.459M by 337.14%. Cara Therapeutics's net income was $-32.337M, beating the average estimation of $-24.407M by 32.49%. The company's SG&A was $6.59M, missing the average forecast of $8.24M by -20.03%. Lastly, the company's EPS was $-0.59, beating the average prediction of $-0.446 by 32.29%